# Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

> **NCT05203679** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Xinzhi BioMed Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** Single dose intravenous injection of BBM-H901

## Key facts

- **NCT ID:** NCT05203679
- **Lead sponsor:** Shanghai Xinzhi BioMed Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-30
- **Primary completion:** 2024-04-16
- **Final completion:** 2028-06-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203679, "Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05203679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*